Search Results

You are looking at 1 - 10 of 39 items for :

  • "oral chemotherapy" x
  • All content x
Clear All
Full access

Saul N. Weingart, Elizabeth Brown, Peter B. Bach, Kirby Eng, Shirley A. Johnson, Timothy M. Kuzel, Terry S. Langbaum, R. Donald Leedy, Raymond J. Muller, Lee N. Newcomer, Susan O’Brien, Denise Reinke, Mark Rubino, Leonard Saltz, and Ronald S. Walters

, ushering in a new era of oral chemotherapy. Capecitabine approval was followed by FDA approval of a number of oral small molecule inhibitors of a variety of defined targets, including imatinib in 2001, gefitinib in 2003, and erlotinib in 2004. Five more new

Full access

Siu-Fun Wong, Mark Bounthavong, Cham P. Nguyen, and Timothy Chen

chemotherapy agents in development are oral agents with multiple-day dosing regimens. 1 The increased availability of oral chemotherapy drugs has shifted drug administration from a supervised to a self-managed setting. 1 Regimens using oral chemotherapy drugs

Full access

Nikhil Khandelwal, Ian Duncan, Tamim Ahmed, Elan Rubinstein, and Cheryl Pegus

Several oral chemotherapies and biologic therapies have been introduced in the past decade for use alone and combined with intravenous chemotherapy. The role of oral chemotherapy agents in cancer management will likely increase. 1 Oral

Full access

Megan Gershon, Justine Pena, Chamnjot Bains, Sarah Salas, Tresa McGranahan, and Seema Nagpal

Background: The development of oral chemotherapies (OC) have transformed cancer care for millions of patients. Most patients with brain tumors have temozolomide (TMZ) delivered to their home. While this has improved the patient experience, it

Full access

Jamie M. Jacobs, Molly E. Ream, Nicole Pensak, Lauren E. Nisotel, Joel N. Fishbein, James J. MacDonald, Joanne Buzaglo, Inga T. Lennes, Steven A. Safren, William F. Pirl, Jennifer S. Temel, and Joseph A. Greer

are presented in Table 1 . A list of oral chemotherapy and targeted therapy drugs is provided in eAppendix 1 (available with this article at JNCCN.org ). Analyses were first conducted with complete case analysis (n=149 for analyses including the

Full access

Katy Winckworth-Prejsnar, Elizabeth A. Nardi, James McCanney, F. Marc Stewart, Terry Langbaum, Bruce J. Gould, C. Lyn Fitzgerald, and Robert W. Carlson

, chemotherapy, and other high-risk treatments. Changing paradigms in cancer treatment, including oral chemotherapy, personalized medicine, biosimilars, and immunotherapy, create evolving safety challenges for the oncology community. Moreover, shifting federal

Full access

Jennifer Hinkel

References 1. Second Annual NCCN Patient Safety Summit, Transcript. Memorial Sloan-Kettering Cancer Center, October 12 , 2006 . 2. Weingart SN Flug J Brouillard D . Oral chemotherapy safety practices at US cancer centers

Full access

Catherine Yip, Evangelia Valilis, Laura Prichett, Catherine Burdalski, and Josephine Feliciano

chemotherapy, 25 IV chemotherapy, and 3 IV immunotherapy. Of 937 patients diagnosed with metastatic NSCLC, 135 (14%) were treated within 30 days of death. 48 received oral targeted therapy, 4 oral chemotherapy, 61 IV chemotherapy, and 21 IV immunotherapy

Full access

Julia C. Shih and Anthony J. Olszanski

significantly lower rates of clinician documentation of treatment plan discussions for oral chemotherapy than for intravenous chemotherapy, per measures outlined in the ASCO Quality Oncology Practice Initiative. 1 However, the continued shortage of medical

Full access

Joseph A. Greer, Jamie M. Jacobs, Nicole Pensak, Lauren E. Nisotel, Joel N. Fishbein, James J. MacDonald, Molly E. Ream, Emily A. Walsh, Joanne Buzaglo, Alona Muzikansky, Inga T. Lennes, Steven A. Safren, William F. Pirl, and Jennifer S. Temel

/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy . J Oncol Pract 2013 ; 9 ( Suppl 2S ): 5s – 13s . 10.1200/JOP.2013.000874 2. Liu G , Franssen E